Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLD-0915
- Development stage
- Phase 2
- Lead developer
- Halda Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
HLD-0915 is an orally bioavailable, heterobifunctional small molecule developed using the Regulated Induced Proximity Targeting Chimera (RIPTAC™) platform. It is designed to treat metastatic castration-resistant prostate cancer (mCRPC) by leveraging the expression of the full-length Androgen Receptor (AR) in tumor cells. The molecule functions via a "hold and kill" mechanism, where it induces the formation of a stable trimeric complex between the AR and an essential protein (EP) required for cell survival. This interaction leads to the loss of function of the essential protein specifically within AR-expressing cancer cells, resulting in selective apoptosis and tumor regression. HLD-0915 is intended to overcome resistance to traditional androgen receptor pathway inhibitors (ARPIs) and other standard-of-care therapies, as its activity depends on the presence of the AR protein rather than its signaling activity.
- Other names
- RIPTACRegulated Induced Proximity Targeting Chimera
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on HLD-0915.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLD-0915.